All In Biotech

Drug Trial Radar · NCT06981806

Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma

IIT2023-07-Osipov-CXCR4: Phase I Dose Escalation and Dose Expansion Study of Combination Immunotherapy With Cosibelimab and CXCR4 Inhibition With Balixafortide in Metastatic Treatment Refractory Pancreatic Ductal Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Jan 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
Arsen OsipovAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed after SOC chemotherapy.

Conditions

  • Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

  • BalixafortideDrug

    Dose: 7.5 mg/kg Route: IV (2hr) Frequency: Weekly

  • BalixafortideDrug

    Dose: 11 mg/kg Route: IV (2hr) Frequency: Weekly

  • CosibelimabDrug

    Dose: 800 mg Route: IV (60 min) Frequency: Weekly

  • BalixafortideDrug

    Dose: 16 mg/kg Route: IV (2hr) Frequency: Weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MTD of BalixafortideTime frame: 2 Years
  2. RP2D of BalixafortideTime frame: 2 Years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Cancer at SOCC

    Los Angeles, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.